Amid conflict concerns, industry wants bigger slice of $3bn Calif stem cell initiative
This article was originally published in Scrip
Executive Summary
The $3.0 billion state initiative in California promoting stem cell research has failed so far to stimulate commercial stem cell operations, companies and investors argued at a 10 April public hearing at the University of California, Irvine. Critics complained that too much of the money dispensed so far has gone to academic research groups, a pattern reinforced as early commercial development have hit hurdles. But some industry representatives predicted that companies would reap greater benefits from a subsequent phase of the initiative that focuses on translational work.